| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 32 | 2024 | 95 | 11.580 |
Why?
|
| Survivors | 46 | 2023 | 234 | 8.680 |
Why?
|
| Neoplasms | 53 | 2024 | 3082 | 6.160 |
Why?
|
| Neoplasms, Second Primary | 22 | 2024 | 260 | 5.000 |
Why?
|
| Hodgkin Disease | 15 | 2024 | 181 | 3.530 |
Why?
|
| Neuroblastoma | 9 | 2024 | 400 | 3.070 |
Why?
|
| Radiotherapy | 14 | 2022 | 334 | 2.460 |
Why?
|
| Child | 66 | 2024 | 7209 | 2.350 |
Why?
|
| Neoplasms, Radiation-Induced | 14 | 2021 | 109 | 2.070 |
Why?
|
| Young Adult | 51 | 2024 | 6360 | 1.750 |
Why?
|
| Resilience, Psychological | 2 | 2024 | 31 | 1.730 |
Why?
|
| Adolescent | 56 | 2024 | 9295 | 1.650 |
Why?
|
| Breast Neoplasms | 21 | 2023 | 3019 | 1.650 |
Why?
|
| Incidence | 18 | 2024 | 1599 | 1.150 |
Why?
|
| Humans | 110 | 2024 | 89760 | 1.140 |
Why?
|
| Colorectal Neoplasms | 7 | 2022 | 983 | 1.130 |
Why?
|
| Adult | 60 | 2024 | 26742 | 1.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2021 | 540 | 1.080 |
Why?
|
| Sarcoma | 3 | 2015 | 220 | 1.060 |
Why?
|
| Early Detection of Cancer | 7 | 2022 | 419 | 1.020 |
Why?
|
| Medical Oncology | 5 | 2019 | 385 | 0.970 |
Why?
|
| Female | 73 | 2024 | 46439 | 0.950 |
Why?
|
| Alphapapillomavirus | 2 | 2021 | 45 | 0.940 |
Why?
|
| Chronic Disease | 5 | 2023 | 950 | 0.910 |
Why?
|
| Risk Factors | 25 | 2024 | 5522 | 0.860 |
Why?
|
| Pediatrics | 4 | 2020 | 357 | 0.850 |
Why?
|
| Child, Preschool | 23 | 2024 | 3752 | 0.840 |
Why?
|
| United States | 27 | 2024 | 7037 | 0.790 |
Why?
|
| Frailty | 1 | 2023 | 78 | 0.780 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 20 | 0.780 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2012 | 112 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2019 | 605 | 0.750 |
Why?
|
| Male | 55 | 2024 | 42632 | 0.740 |
Why?
|
| Infant | 19 | 2024 | 3171 | 0.720 |
Why?
|
| Cohort Studies | 15 | 2023 | 2882 | 0.710 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 2416 | 0.700 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 28 | 0.700 |
Why?
|
| Leukemia | 3 | 2024 | 323 | 0.680 |
Why?
|
| Telemedicine | 1 | 2022 | 188 | 0.660 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 261 | 0.640 |
Why?
|
| Patient Education as Topic | 3 | 2019 | 365 | 0.640 |
Why?
|
| Quality of Life | 7 | 2024 | 1676 | 0.640 |
Why?
|
| Attitude of Health Personnel | 3 | 2014 | 651 | 0.620 |
Why?
|
| Alcohol Drinking | 3 | 2020 | 273 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2568 | 0.610 |
Why?
|
| Longevity | 1 | 2018 | 58 | 0.600 |
Why?
|
| Aftercare | 1 | 2019 | 87 | 0.600 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 714 | 0.590 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 47 | 0.580 |
Why?
|
| Anthracyclines | 4 | 2023 | 38 | 0.570 |
Why?
|
| Retrospective Studies | 20 | 2022 | 9100 | 0.560 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 144 | 0.560 |
Why?
|
| Adenoma | 1 | 2018 | 247 | 0.530 |
Why?
|
| Depression | 1 | 2020 | 509 | 0.520 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2016 | 40 | 0.520 |
Why?
|
| Middle Aged | 33 | 2024 | 26129 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 891 | 0.490 |
Why?
|
| Transition to Adult Care | 1 | 2015 | 22 | 0.480 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 182 | 0.480 |
Why?
|
| Precision Medicine | 1 | 2019 | 414 | 0.470 |
Why?
|
| Population Surveillance | 7 | 2020 | 216 | 0.460 |
Why?
|
| Ambulatory Care | 1 | 2015 | 188 | 0.460 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 27 | 0.450 |
Why?
|
| Canada | 7 | 2021 | 209 | 0.450 |
Why?
|
| Computer Simulation | 1 | 2018 | 1102 | 0.440 |
Why?
|
| SEER Program | 4 | 2021 | 199 | 0.440 |
Why?
|
| Proportional Hazards Models | 7 | 2024 | 856 | 0.440 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 11 | 0.430 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 69 | 0.430 |
Why?
|
| Hearing Loss | 1 | 2013 | 62 | 0.430 |
Why?
|
| Patient Safety | 1 | 2015 | 217 | 0.430 |
Why?
|
| Physicians, Family | 1 | 2013 | 39 | 0.420 |
Why?
|
| Age Factors | 12 | 2019 | 1876 | 0.420 |
Why?
|
| Methyltransferases | 1 | 2013 | 192 | 0.410 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 118 | 0.390 |
Why?
|
| Disease-Free Survival | 4 | 2018 | 1218 | 0.390 |
Why?
|
| Mass Screening | 7 | 2022 | 642 | 0.380 |
Why?
|
| Cisplatin | 1 | 2013 | 618 | 0.380 |
Why?
|
| Risk Assessment | 11 | 2021 | 2309 | 0.380 |
Why?
|
| Continuity of Patient Care | 2 | 2010 | 172 | 0.380 |
Why?
|
| Time Factors | 12 | 2024 | 5346 | 0.370 |
Why?
|
| Mammography | 7 | 2022 | 474 | 0.360 |
Why?
|
| Delivery of Health Care | 7 | 2022 | 436 | 0.340 |
Why?
|
| Surveys and Questionnaires | 9 | 2022 | 2643 | 0.340 |
Why?
|
| Survival Rate | 6 | 2020 | 1910 | 0.340 |
Why?
|
| Risk | 3 | 2021 | 657 | 0.330 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2024 | 67 | 0.330 |
Why?
|
| Aging | 1 | 2014 | 721 | 0.320 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 3672 | 0.320 |
Why?
|
| Prognosis | 6 | 2020 | 3802 | 0.320 |
Why?
|
| Health Status Disparities | 1 | 2010 | 191 | 0.310 |
Why?
|
| Odds Ratio | 4 | 2012 | 684 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1050 | 0.300 |
Why?
|
| Infant, Newborn | 7 | 2023 | 2488 | 0.290 |
Why?
|
| Sarcoma, Ewing | 2 | 2017 | 44 | 0.280 |
Why?
|
| Self Report | 2 | 2020 | 297 | 0.280 |
Why?
|
| Quality of Health Care | 1 | 2010 | 386 | 0.280 |
Why?
|
| Genetic Variation | 1 | 2013 | 1380 | 0.280 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 1078 | 0.270 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2019 | 188 | 0.270 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1864 | 0.260 |
Why?
|
| Radiation Injuries | 2 | 2019 | 162 | 0.260 |
Why?
|
| Treatment Outcome | 12 | 2022 | 8283 | 0.260 |
Why?
|
| Immunotherapy | 2 | 2022 | 693 | 0.260 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 329 | 0.250 |
Why?
|
| Residence Characteristics | 3 | 2021 | 203 | 0.250 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 1721 | 0.240 |
Why?
|
| Doxorubicin | 3 | 2023 | 303 | 0.240 |
Why?
|
| Bone Density Conservation Agents | 2 | 2019 | 46 | 0.230 |
Why?
|
| Polyketides | 1 | 2023 | 1 | 0.230 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 28 | 0.220 |
Why?
|
| Aorta, Thoracic | 3 | 1994 | 168 | 0.220 |
Why?
|
| Vincristine | 3 | 2022 | 112 | 0.220 |
Why?
|
| Insurance Coverage | 1 | 2024 | 122 | 0.220 |
Why?
|
| Osteoporosis | 2 | 2019 | 122 | 0.220 |
Why?
|
| Insurance, Health | 1 | 2024 | 163 | 0.220 |
Why?
|
| Health Behavior | 3 | 2016 | 186 | 0.210 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2022 | 2 | 0.210 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2023 | 91 | 0.210 |
Why?
|
| North America | 4 | 2019 | 185 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1721 | 0.210 |
Why?
|
| Procarbazine | 2 | 2012 | 40 | 0.210 |
Why?
|
| Platinum Compounds | 2 | 2012 | 31 | 0.210 |
Why?
|
| Exercise | 3 | 2021 | 325 | 0.200 |
Why?
|
| Morbidity | 1 | 2022 | 149 | 0.200 |
Why?
|
| Radiation Dosage | 2 | 2019 | 227 | 0.200 |
Why?
|
| Prevalence | 4 | 2021 | 1246 | 0.200 |
Why?
|
| Bleomycin | 2 | 2022 | 102 | 0.200 |
Why?
|
| Etoposide | 2 | 2022 | 206 | 0.190 |
Why?
|
| Prednisone | 2 | 2022 | 259 | 0.190 |
Why?
|
| Cyclophosphamide | 2 | 2022 | 302 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2022 | 148 | 0.190 |
Why?
|
| Radiotherapy Dosage | 4 | 2019 | 470 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 58 | 0.180 |
Why?
|
| Recurrence | 3 | 2019 | 1144 | 0.180 |
Why?
|
| Papillomaviridae | 1 | 2021 | 157 | 0.180 |
Why?
|
| Immunologic Factors | 1 | 2022 | 172 | 0.180 |
Why?
|
| Withholding Treatment | 1 | 2021 | 117 | 0.180 |
Why?
|
| Aged | 11 | 2022 | 19280 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 202 | 0.180 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1152 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2014 | 234 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 684 | 0.170 |
Why?
|
| Heart Diseases | 2 | 2020 | 298 | 0.170 |
Why?
|
| Genetic Testing | 1 | 2024 | 540 | 0.170 |
Why?
|
| Tamoxifen | 1 | 2020 | 168 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 2355 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 8 | 0.170 |
Why?
|
| Research Report | 1 | 2019 | 44 | 0.170 |
Why?
|
| Siblings | 4 | 2024 | 111 | 0.170 |
Why?
|
| Transitional Care | 1 | 2019 | 18 | 0.170 |
Why?
|
| Poverty | 1 | 2021 | 183 | 0.170 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 24 | 0.170 |
Why?
|
| American Cancer Society | 1 | 2019 | 13 | 0.160 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 34 | 0.160 |
Why?
|
| Imidazoles | 2 | 2007 | 148 | 0.160 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 166 | 0.160 |
Why?
|
| Professional Practice | 1 | 2019 | 46 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 97 | 0.160 |
Why?
|
| Needs Assessment | 2 | 2017 | 161 | 0.160 |
Why?
|
| Clinical Competence | 2 | 2016 | 785 | 0.160 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 47 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 6847 | 0.150 |
Why?
|
| Medicaid | 2 | 2024 | 235 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1370 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 263 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 10 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2018 | 83 | 0.150 |
Why?
|
| Anxiety | 1 | 2020 | 311 | 0.150 |
Why?
|
| Vinblastine | 1 | 2017 | 108 | 0.150 |
Why?
|
| Age of Onset | 2 | 2021 | 313 | 0.140 |
Why?
|
| Health Status | 2 | 2016 | 371 | 0.140 |
Why?
|
| Dacarbazine | 1 | 2017 | 102 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2017 | 133 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2023 | 177 | 0.140 |
Why?
|
| Campylobacter | 1 | 2016 | 5 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 147 | 0.140 |
Why?
|
| Campylobacter Infections | 1 | 2016 | 12 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 85 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 2025 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 212 | 0.130 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2015 | 1 | 0.130 |
Why?
|
| State Health Plans | 1 | 1996 | 14 | 0.130 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2015 | 9 | 0.130 |
Why?
|
| Global Health | 1 | 2017 | 192 | 0.130 |
Why?
|
| Managed Care Programs | 1 | 1996 | 42 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 192 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 416 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 290 | 0.130 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 35 | 0.130 |
Why?
|
| Comorbidity | 3 | 2016 | 951 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 776 | 0.120 |
Why?
|
| Breast | 3 | 2023 | 292 | 0.120 |
Why?
|
| Health Services | 1 | 2015 | 57 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 162 | 0.120 |
Why?
|
| Community Health Centers | 1 | 1996 | 117 | 0.120 |
Why?
|
| Curriculum | 2 | 2016 | 568 | 0.120 |
Why?
|
| Blood Volume | 1 | 1994 | 49 | 0.110 |
Why?
|
| Thoracic Wall | 1 | 2014 | 25 | 0.110 |
Why?
|
| Postal Service | 2 | 2012 | 17 | 0.110 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 179 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 785 | 0.110 |
Why?
|
| Rural Health | 2 | 2024 | 21 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 559 | 0.110 |
Why?
|
| Minority Groups | 1 | 2015 | 147 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 797 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 288 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 277 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 310 | 0.110 |
Why?
|
| Smoking | 2 | 2015 | 624 | 0.110 |
Why?
|
| Cacao | 1 | 2012 | 4 | 0.100 |
Why?
|
| Beverages | 1 | 2012 | 17 | 0.100 |
Why?
|
| Hemostasis | 1 | 2012 | 21 | 0.100 |
Why?
|
| Health Care Surveys | 2 | 2012 | 281 | 0.100 |
Why?
|
| Tea | 1 | 2012 | 21 | 0.100 |
Why?
|
| Prazosin | 1 | 1992 | 10 | 0.100 |
Why?
|
| Receptors, Adrenergic | 1 | 1992 | 15 | 0.100 |
Why?
|
| Enalapril | 1 | 1992 | 13 | 0.100 |
Why?
|
| Motor Activity | 1 | 2015 | 328 | 0.100 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1992 | 31 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 394 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 105 | 0.100 |
Why?
|
| Propranolol | 1 | 1992 | 44 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 226 | 0.100 |
Why?
|
| Renin-Angiotensin System | 1 | 1992 | 81 | 0.100 |
Why?
|
| Students, Medical | 1 | 2016 | 421 | 0.090 |
Why?
|
| Medically Uninsured | 2 | 2024 | 59 | 0.090 |
Why?
|
| Thorax | 1 | 2010 | 77 | 0.090 |
Why?
|
| Wilms Tumor | 1 | 2010 | 38 | 0.090 |
Why?
|
| Survivorship | 2 | 2021 | 20 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2012 | 353 | 0.090 |
Why?
|
| Internal Medicine | 1 | 2014 | 357 | 0.090 |
Why?
|
| Vision Disorders | 1 | 2010 | 75 | 0.090 |
Why?
|
| Rural Population | 2 | 2024 | 146 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2010 | 61 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1682 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2010 | 102 | 0.080 |
Why?
|
| Hemodynamics | 2 | 1993 | 731 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2012 | 458 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 972 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 231 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 168 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2009 | 900 | 0.080 |
Why?
|
| Physicians | 2 | 2016 | 691 | 0.080 |
Why?
|
| Biomedical Research | 2 | 2024 | 400 | 0.080 |
Why?
|
| Nephrectomy | 1 | 2010 | 295 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2007 | 36 | 0.070 |
Why?
|
| Health Promotion | 1 | 2009 | 165 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2010 | 1535 | 0.070 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2007 | 108 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 343 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2022 | 4328 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 138 | 0.070 |
Why?
|
| Michigan | 2 | 2016 | 53 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1944 | 0.070 |
Why?
|
| Logistic Models | 1 | 2009 | 1215 | 0.070 |
Why?
|
| Fatty Acids, Essential | 1 | 2005 | 1 | 0.070 |
Why?
|
| Fish Oils | 1 | 2005 | 14 | 0.060 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2005 | 16 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 846 | 0.060 |
Why?
|
| Molluscacides | 2 | 1996 | 2 | 0.060 |
Why?
|
| Plants, Medicinal | 2 | 1996 | 42 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2016 | 3400 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 591 | 0.060 |
Why?
|
| Rural Health Services | 1 | 2024 | 17 | 0.060 |
Why?
|
| Mutation | 1 | 2016 | 4167 | 0.060 |
Why?
|
| Spouses | 1 | 2023 | 32 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2024 | 115 | 0.060 |
Why?
|
| Daunorubicin | 1 | 2023 | 78 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 601 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2024 | 116 | 0.050 |
Why?
|
| Urban Health | 1 | 2003 | 56 | 0.050 |
Why?
|
| Poisson Distribution | 2 | 2015 | 50 | 0.050 |
Why?
|
| Family Practice | 1 | 2003 | 82 | 0.050 |
Why?
|
| Patient Admission | 1 | 2003 | 114 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2022 | 73 | 0.050 |
Why?
|
| Radiometry | 1 | 2022 | 56 | 0.050 |
Why?
|
| Sex Factors | 2 | 2015 | 1070 | 0.050 |
Why?
|
| Research | 1 | 2022 | 252 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2021 | 23 | 0.050 |
Why?
|
| Ohio | 1 | 2021 | 40 | 0.050 |
Why?
|
| Attitude to Health | 2 | 2015 | 223 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 431 | 0.050 |
Why?
|
| Social Isolation | 1 | 2021 | 67 | 0.050 |
Why?
|
| Medically Underserved Area | 2 | 2003 | 27 | 0.050 |
Why?
|
| Organs at Risk | 1 | 2020 | 40 | 0.050 |
Why?
|
| Breast Density | 1 | 2020 | 36 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 164 | 0.050 |
Why?
|
| Health Surveys | 1 | 2021 | 240 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 860 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2015 | 774 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 463 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 1201 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 270 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2022 | 451 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 142 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2019 | 32 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 276 | 0.040 |
Why?
|
| Family | 1 | 2021 | 325 | 0.040 |
Why?
|
| Blood Pressure | 2 | 1994 | 903 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 125 | 0.040 |
Why?
|
| raf Kinases | 1 | 2017 | 12 | 0.040 |
Why?
|
| Parents | 1 | 2021 | 288 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 426 | 0.040 |
Why?
|
| Gonadal Hormones | 1 | 2017 | 2 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 360 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2766 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 864 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 309 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 1 | 2017 | 34 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1413 | 0.030 |
Why?
|
| Chicago | 1 | 2021 | 1436 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 426 | 0.030 |
Why?
|
| Rhode Island | 1 | 1996 | 10 | 0.030 |
Why?
|
| Behavior | 1 | 2016 | 85 | 0.030 |
Why?
|
| Oregon | 1 | 1996 | 26 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 148 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 576 | 0.030 |
Why?
|
| Saponins | 1 | 1996 | 42 | 0.030 |
Why?
|
| Transients and Migrants | 1 | 1996 | 7 | 0.030 |
Why?
|
| Dogs | 2 | 1994 | 704 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2012 | 1724 | 0.030 |
Why?
|
| Models, Organizational | 1 | 1996 | 47 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 195 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 149 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 1996 | 36 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1793 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2017 | 161 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 1995 | 45 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2015 | 39 | 0.030 |
Why?
|
| Orthopedic Procedures | 1 | 2017 | 129 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 123 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 39 | 0.030 |
Why?
|
| Asthma | 1 | 2003 | 980 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 173 | 0.030 |
Why?
|
| DNA Repair | 1 | 2016 | 364 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 265 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1994 | 4 | 0.030 |
Why?
|
| Whole-Body Counting | 1 | 1994 | 7 | 0.030 |
Why?
|
| Oleanolic Acid | 1 | 1993 | 7 | 0.030 |
Why?
|
| Mutagens | 1 | 1993 | 31 | 0.030 |
Why?
|
| Fabaceae | 1 | 1993 | 25 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 873 | 0.030 |
Why?
|
| Health Personnel | 1 | 2016 | 215 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 221 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 344 | 0.030 |
Why?
|
| International Cooperation | 1 | 2013 | 125 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1995 | 432 | 0.030 |
Why?
|
| Muscles | 1 | 1993 | 193 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2015 | 497 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 131 | 0.030 |
Why?
|
| Flavonols | 1 | 2012 | 1 | 0.030 |
Why?
|
| District of Columbia | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 1993 | 172 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2012 | 53 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1993 | 245 | 0.030 |
Why?
|
| Constriction | 1 | 1992 | 27 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2015 | 321 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1558 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1993 | 316 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 426 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 988 | 0.030 |
Why?
|
| Communication | 1 | 2016 | 460 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2665 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2015 | 327 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 312 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 1992 | 103 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 579 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1992 | 155 | 0.020 |
Why?
|
| Japan | 1 | 2012 | 305 | 0.020 |
Why?
|
| Plant Extracts | 1 | 1993 | 245 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 389 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 119 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 498 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2012 | 93 | 0.020 |
Why?
|
| Antioxidants | 1 | 2012 | 226 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 434 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 741 | 0.020 |
Why?
|
| Northern Territory | 1 | 2010 | 1 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2010 | 36 | 0.020 |
Why?
|
| Myocardium | 1 | 1993 | 572 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 242 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 792 | 0.020 |
Why?
|
| Animals | 6 | 1996 | 27456 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Rosacea | 1 | 1989 | 1 | 0.020 |
Why?
|
| Metronidazole | 1 | 1989 | 26 | 0.020 |
Why?
|
| Rats | 2 | 1993 | 4044 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 1996 | 315 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 590 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2009 | 56 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 579 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2007 | 24 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2007 | 72 | 0.020 |
Why?
|
| Melanoma | 1 | 2010 | 470 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 209 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2009 | 255 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 1771 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2019 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 584 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2005 | 63 | 0.020 |
Why?
|
| Energy Intake | 1 | 2005 | 99 | 0.020 |
Why?
|
| Biomphalaria | 2 | 1996 | 2 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 149 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 283 | 0.010 |
Why?
|
| Victoria | 1 | 2003 | 5 | 0.010 |
Why?
|
| Small-Area Analysis | 1 | 2003 | 8 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2005 | 237 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 172 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 200 | 0.010 |
Why?
|
| Health Services Research | 1 | 2003 | 137 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 2003 | 147 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3473 | 0.010 |
Why?
|
| Length of Stay | 1 | 2003 | 742 | 0.010 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1996 | 3 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1996 | 9 | 0.010 |
Why?
|
| Ethiopia | 1 | 1996 | 37 | 0.010 |
Why?
|
| Candida albicans | 1 | 1996 | 32 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1995 | 53 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 1995 | 40 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1996 | 150 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 1995 | 69 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 1995 | 76 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1995 | 90 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1995 | 203 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 696 | 0.010 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1993 | 18 | 0.010 |
Why?
|
| Biotransformation | 1 | 1993 | 50 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1995 | 466 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 1993 | 14 | 0.010 |
Why?
|
| Salmonella typhimurium | 1 | 1993 | 33 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 1993 | 127 | 0.010 |
Why?
|
| Phosphorus | 1 | 1993 | 117 | 0.010 |
Why?
|
| Phosphates | 1 | 1993 | 161 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 447 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1993 | 503 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 996 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 2496 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1993 | 607 | 0.010 |
Why?
|
| Facial Dermatoses | 1 | 1989 | 13 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1989 | 96 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 1995 | 3229 | 0.000 |
Why?
|
| Mice | 1 | 1995 | 11814 | 0.000 |
Why?
|